Andover, MA, United States of America

Huiming Zhang

USPTO Granted Patents = 10 


 

Average Co-Inventor Count = 5.0

ph-index = 5

Forward Citations = 82(Granted Patents)


Company Filing History:


Years Active: 2013-2021

Loading Chart...
Loading Chart...
Loading Chart...
10 patents (USPTO):

Title: Huiming Zhang: Innovator in Cancer Treatment

Introduction

Huiming Zhang is a prominent inventor based in Andover, MA (US), known for his significant contributions to the field of cancer treatment. With a total of 10 patents, he has made remarkable strides in developing innovative therapies aimed at combating various forms of cancer.

Latest Patents

Among his latest patents, Zhang has developed multikinase inhibitors for use in the treatment of cancer. This invention provides compounds, pharmaceutical compositions, and methods specifically designed for treating certain cancers. The compositions generally comprise a compound of formula (I), wherein R-Rare is defined within the patent, or pharmaceutically acceptable salts or esters thereof, along with a pharmaceutically acceptable carrier. Additionally, he has improved methods useful for the synthesis of halichondrin B analogs, such as eribulin and its pharmaceutically acceptable salts, including eribulin mesylate.

Career Highlights

Throughout his career, Huiming Zhang has worked with notable companies, including Eisai R&D Management Co., Ltd. and Eisai Inc. His work has been instrumental in advancing cancer therapies and improving patient outcomes.

Collaborations

Zhang has collaborated with esteemed colleagues, including Bryan Matthew Lewis and Yongbo Hu, contributing to the development of innovative solutions in the pharmaceutical industry.

Conclusion

Huiming Zhang's dedication to cancer research and his innovative patents highlight his role as a key figure in the fight against cancer. His work continues to inspire advancements in medical treatments and therapies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…